Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dual Immune Checkpoint Blockade in Locally Advanced NSCLC
NCT07103395Phase 2Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Jan 2026
- Primary completion
- Dec 2029
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of iparomlimab, tuvonralimab in non-small cell lung cancer (NSCLC), sponsored by Sun Yat-sen University. Started Jan 2026; status: recruiting.
02
Drugs
iparomlimabtuvonralimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07103395.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07103395.